Autor(es): Santana, Wanessa ; de Oliveira, Simone S. C. ; Ramos, Mariana H. ; Santos, André L. S. ; Dolabella, Silvio S. ; Souto, Eliana B. ; Severino, Patrícia ; Jain, Sona
Data: 2021
Identificador Persistente: https://hdl.handle.net/1822/74070
Origem: RepositóriUM - Universidade do Minho
Assunto(s): Leishmaniasis; New targets; Pre-clinical; Clinical; Drug repurposing
Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (invitro, invivo), drug repurposing and clinical research.
